### Legal Turbulence in the Hemp Industry
As the hemp industry grapples with the impending changes from Congress’s recent efforts to close the hemp loophole, a wave of legal uncertainty looms over businesses specializing in hemp beverages and edibles. Set to take effect next October, the new legislation aims primarily at curtailing the proliferation of intoxicating cannabinoids like THCV. However, the bill’s broader structure threatens to impact a wider range of hemp businesses than anticipated.
### Unintended Consequences for CBD Manufacturers
One of the critical concerns raised by industry experts revolves around the potential fallout for CBD isolate manufacturers. These companies, while producing non-intoxicating products, might find themselves caught in the crossfire of stricter regulations. Jason Adelstone, an attorney with Harris Sliwoski, notes that extracting CBD can transiently elevate THC levels. He explains that this spike could render their products illegal, creating trepidation among manufacturers about the viability of continuing to offer CBD products amidst heightened scrutiny.
### A Legal Gray Area: Tissue Cultures and Clones
Despite the bill’s sweeping intent, it may inadvertently leave a loophole open regarding tissue cultures and clones. The new legislation states that any hemp or marijuana seed testing above 0.3 percent THC is illegal, but conspicuously absent from this provision are tissue cultures or clones that test below this threshold. According to Adelstone, this oversight is significant as it suggests Congressional intent to keep these practices legal. As a result, businesses can still ship tissue cultures and clones across state lines and even internationally, as long as they comply with the USDA’s phytosanitary requirements.
Delving deeper, Adelstone asserts that tissue cultures are becoming more popular, especially in medical programs, due to their ability to ensure quality control better than seeds, which can produce unpredictable results as they grow.
### Powdered Beverages and New Product Formats
While the legislation has effectively shut down many avenues for hemp-derived beverages and edibles, it has imposed a 4% THC limit per container for the first time. This limitation could inadvertently push manufacturers to pivot toward powdered beverage formats, allowing consumers to dose according to their preferences.
### Regulatory Ambiguities: The Stalks of the Plant
Another notable gap in the legislation pertains to hemp and marijuana stalks. Though both plants have distinct regulatory frameworks, stalks were not included in the new legal definitions. While not the ideal source for cannabinoid extraction, their processing is still feasible when dealing with large volumes of biomass. Adelstone mentions that companies might explore producing extracts from stalks with high THC content, which would remain unregulated under the CSA, creating a potential gray area in legal interpretation.
### Impact of Rescheduling on the Hemp Industry
Following the closure of the hemp loophole, the industry faces additional challenges as hemp-derived businesses now fall under the 280E tax rule. This development carries significant implications, as it prevents operators from deducting business expenses—resulting in a substantial financial burden. Moreover, even if cannabis transitions to Schedule 3 status, many operational restrictions, such as interstate transport limitations, will likely remain intact.
### International Insights from Thailand
Jason Adelstone recently attended the International Asian Hemp Expo in Bangkok, where he witnessed firsthand the evolving cannabis landscape in Thailand. Here, the Ministry of Health has reverted to a medical-only framework, although the enforcement remains inconsistent. Despite the technical prohibition on recreational cannabis, consumers, including tourists, still find ways to access medicinal products, leading to a rather gray market within a legal system.
Adelstone emphasizes that Thailand’s earlier decision to deschedule cannabis lacked an accompanying regulatory framework, leading to widespread access to unregulated products. As both local and international businesses engage in legal cultivation practices, regulatory development remains pivotal for ensuring quality, safety, and public health.
### Preparing for International Trade: The DEA Registrations
The prospect of international trade looms large for the cannabis industry, with Adelstone advising larger companies to seek DEA registrations proactively. While only a handful of such registrations exist—many inactive—holding one could position companies favorably for future international medical cannabis opportunities.
Moreover, a proactive administration could expedite regulatory expansions without needing Congressional approval. By empowering the DEA to facilitate interstate transport and broaden approval scopes for medical cannabis, a call for stricter adherence to legislative changes is underscored.
### Supply Chain Liability Concerns in the Cannabis Sector
The cannabis industry faces increasing scrutiny regarding product quality, particularly as recalls related to terpene loss and potency degradation rise. As various entities in the supply chain may be held liable, companies must navigate the complexities of ensuring product integrity from manufacturer to consumer. The temperature-sensitive nature of cannabis products adds an extra layer of urgency, as improper handling can lead to significant losses.
Adelstone warns that the lack of a standardized cold-chain infrastructure will only exacerbate these challenges. As recalls become more frequent, determining accountability in the supply chain becomes critical for maintaining consumer trust and safety.